SAM
EGRX

Symphony Asset Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Symphony Asset Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-4,250
Closed -$253K – 383
2017
Q3 		$253K Sell
4,250
-282
-6% -$17.1K 0.03% 324
2017
Q2 		$358K Sell
4,532
-1,658
-27% -$136K 0.04% 301
2017
Q1 		$513K Buy
+6,190
New +$460K 0.05% 286

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Symphony Asset Management's EGRX Position: Q4 2017 in Review

Symphony Asset Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2017, closing a stake of 4,250 shares — an estimated $253K sold.

Symphony Asset Management first reported a position in EGRX in Q1 2017 and held it in 3 quarters. The position peaked at $513K in Q1 2017. 170 funds tracked by Wall St. Rank hold EGRX as of Q4 2017.

  • Symphony Asset Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Symphony Asset Management sold 4,250 Eagle Pharmaceuticals, Inc. shares in Q4 2017, an estimated $253K.
  • Symphony Asset Management first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2017 and held it in 3 quarters.
  • Symphony Asset Management's Eagle Pharmaceuticals, Inc. position peaked at $513K in Q1 2017.
  • 170 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2017.

Based on Symphony Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.